Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Pacira BioSciences (PCRX)

Pacira shareholders elect three directors and approve 800,000-share ESPP increase

Neutral Impact 2 of 5 shareholder Written later

At its June 9, 2026 annual meeting, Pacira stockholders re-elected Christopher J. Christie, Samit Hirawat and Thomas Wiggans as Class III directors, approved an amended 2014 Employee Stock Purchase Plan adding 800,000 shares, and ratified KPMG LLP as auditor for 2026. The filing also reports a vote on an amended 2011 Stock Incentive Plan in which more votes were cast against than for, and it discloses board committee reassignments.

Key points

  • Christie, Hirawat and Wiggans elected to serve until the 2029 annual meeting; Christie received 24,963,961 for and 7,675,321 withheld votes.
  • ESPP amendment approved, adding 800,000 newly reserved shares, effective immediately upon approval.
  • Proposal 4, amended 2011 Stock Incentive Plan: 14,178,418 for and 18,405,754 against; the filing does not state the outcome.
  • KPMG LLP ratified as independent auditor with 32,908,044 for and 138,246 against.

The filing

CompanyPacira BioSciences (PCRX)
Form8-K, current report
Filed with the SECJun 11, 2026, 4:32 PM ET
Accession number0001628280-26-042525

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:58 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 11, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.